Janpix
Latest round
- Series B
Last raised
- Oct 2020
Total raised
- $29M
Investors
- 1
About Janpix
Janpix Ltd.Founded in 2013, Janpix Ltd. is based in Cambridge, US. The company specializes in creating targeted cancer therapies, and it has completed 2 deals, with the most recent deal occurring on October 7, 2020.Janpix Ltd. develops cutting-edge therapies aimed at treating various forms of cancer. The company focuses on creating novel drug candidates that leverage advanced scientific techniques to enhance therapeutic efficacy and patient outcomes.Janpix Ltd. aims to expedite the development of new cancer therapies. The company plans to expand its research efforts in specific cancer indications and intends to enhance its portfolio with additional novel drug candidates targeted for release within the next two years. Moreover, Janpix is looking to expand its market reach beyond the US into Europe and Asia by 2023.
Who invested in Janpix
1 investor across 2 rounds
See all investors in Janpix
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Janpix
Who invested in Janpix?
Janpix has 1 investor on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Janpix raised?
Janpix has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Janpix last raise money?
Janpix's most recent round on record is a Series B, in Oct 2020.
What does Janpix do?
Janpix is a biotechnology company.
Where is Janpix headquartered?
Janpix is headquartered in Cambridge, US.
Which VCs invest in companies like Janpix?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Janpix's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Janpix? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.